Regulada
Venta anticipada
- Nivel de riesgo
- Muy alto
- Riesgo-rentabilidad
- Media
- Desde
- €500
Financiación cerrada el 20 Sep 2026. La página sigue disponible como referencia; abajo verá proyectos abiertos similares.
Kairos Discovery
Francia
A Lyon-based biotech developing KDX-350, an oral bivalent CK2 inhibitor for colorectal and clear-cell renal cancer, to license to a pharmaceutical partner from 2027.
Cifras clave
- Rentabilidad estimada
- hasta 20×
- estimación de la plataforma
- Valoración
- €3,294,118
- Participación ofrecida
- 21
- Salida prevista
- 2030
- Fin de la financiación
- 20 Sep 2026
- Desde
- €1,000
- Objetivo
- €850,000
Qué posee, cómo puede dar rentabilidad y cuándo
¿Qué poseo?
21 de la empresa
Consulte en los documentos cómo se mantienen las participaciones y qué derechos otorgan.
¿Cómo puede dar rentabilidad?
La plataforma estima hasta 20×
Normalmente solo si la empresa se vende o sale a bolsa. Las estimaciones son afirmaciones de la propia plataforma.
¿Cuándo podría recibir dinero?
Hacia 2030
Solo si se produce una venta o una salida a bolsa; antes de eso, las participaciones son difíciles de vender.
Capital en riesgo. La mayoría de las startups fracasan; las estimaciones son afirmaciones de la propia plataforma. Las participaciones son difíciles de vender antes de una salida.
¿Invertiría la IA?
IA 63 MediaNuestra IA da a este proyecto 63 de 100: Media. Cómo funciona la puntuación de la IA
Información, no asesoramiento personalizado de inversión. La puntuación IA valora los documentos que publica la plataforma, puede equivocarse y no predice la rentabilidad.
Análisis de la IA
IAKairos Discovery — Crowdfunding Investor Memo
A French laboratory company designing an experimental cancer medicine that it plans to sell or license to a large pharmaceutical company rather than sell to patients itself.
Sector: Biotechnology (preclinical oncology) · Stage: Seed (preclinical) · HQ: Lyon, France · Raise: €850,000 target (maximum €1,500,000)
Snapshot
|
1 · Is the price fair? 💶 |
5 / 5 — Supported. At €2.8M–€3.3M before this round, the price is below every European early-stage benchmark we located: a median of €5.0M in Q3 2025 and €3.6M over the longer term (PitchBook-derived data, November 2025), a typical seed range of €4M–€12M (Startkeel, 2026), and a European early-stage median of $6.54M for 2020–2025 (Equidam, Q3 2025). |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 63 / 100 — Average The strongest evidence is the people and the science: the chairman led a comparable Lyon company to an acquisition by Eli Lilly in 2023, and the underlying research is published in a peer-reviewed chemistry journal with a crystal structure deposited in a public database. The biggest gap is that the medicine being offered here, KDX-350, is not the compound described in that publication, and no data on KDX-350 itself is in the pack we reviewed. |
|
3 · If they do, what could it pay? 🎯 |
Target 20x over 3.5–4.5 years (the company's own plan; the standard expectation for a seed-stage company is about 10x over 5–7 years). If reached, illustratively 5x–50x before fees and before future dilution. Method: the required sale value divided by the €4.09M value of the whole company at this round's price. The low end is a licensing deal at the median upfront payment for a preclinical cancer drug, $22M (Ambrosia Ventures deal database, 2026); the high end is the company's own stated target of more than €200M once the medicine has shown early results in patients. |
How to read the score
|
85–100 · Excellent |
All key preconditions for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Preconditions largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful preconditions missing or weakly evidenced |
|
30–49 · Weak |
Several core preconditions absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental preconditions are not visible in the evidence |
|
What we could check. We checked 33 of the company's claims against public sources. The company registration, its 2023 fundraise, the chairman's previous sale of a business to Eli Lilly, the patent family, the peer-reviewed publication and the French tax ruling all check out against public records. The figures for the medicine itself (KDX-350), the letter of interest from a pharmaceutical company, the current cash position and most of the market-size numbers rest on the company's own materials — see the questions section. Your money is locked in. Crowdfunding shares normally cannot be sold early — expect your money to be tied up for several years, until the company is sold or a similar event happens. |
Three answers, one honest note. The fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the building blocks in place to reach a point where a sale or licensing deal can happen — it audits readiness on the evidence disclosed. It is not a measure of how likely success is, and even companies with every building block in place fail more often than they succeed, which is why this kind of investing only works as a small part of a spread-out portfolio. The returns range is an illustration built from named industry benchmarks, not a forecast. Where something was not in the pack we reviewed, it did not lower any score — it appears in the questions list instead, so you can ask the company directly before you invest. The listing was reviewed by a licensed crowdfunding platform before it went live. Nothing here is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
|
Deal terms. No terms were identified in the reviewed documents that would prevent a crowdfund investor from sharing in the upside. Full mechanics are at the end of this memo. One point to check: the two platform documents disagree on a single right. The official Key Investment Information Sheet states there is no prio… |
El análisis completo cubre al prestatario o la empresa, la garantía, el flujo de caja, los riesgos y un veredicto. Inicie sesión para leerlo.
Información, no asesoramiento personalizado de inversión. La puntuación IA valora los documentos que publica la plataforma, puede equivocarse y no predice la rentabilidad.
Preguntar a la IA sobre este proyecto
Inicie sesión para preguntar a la IA sobre los documentos de este proyecto.
Iniciar sesión¿Le gusta este proyecto?
👍 Sí · 0 👎 No · 0
Comentarios · 0
- Aún no hay comentarios.
La plataforma y proyectos similares
Ofrecido en
Proyectos abiertos similares
Kepplair Evolution
Sowefund
- Rentabilidad estimada
- hasta 7×
- estimación de la plataforma
- Valoración
- €60,000,000
Objetivo: €9m
Desde €500
Ver proyecto
Wind Fisher
Sowefund
- Rentabilidad estimada
- hasta 10×
- estimación de la plataforma
- Valoración
- €9,961,800
Objetivo: €600k
Desde €1,000
Ver proyecto
Blumana
Sowefund
- Rentabilidad estimada
- hasta 28×
- estimación de la plataforma
- Valoración
- €2,799,571
Objetivo: €750k
Desde €1,000
Ver proyecto